When Liver Disease Raises Pressure in the Lungs: The Overlooked Story of Portopulmonary Hypertension

Portopulmonary hypertension is one of the lesser-known but important complications that can happen in people with portal hypertension, cirrhosis, or advanced liver disease. Many patients first hear the term during a liver transplant evaluation, after an echocardiogram suggests high pressure in the blood vessels of the lungs. Others may be investigated because they have shortness of breath, tiredness, chest discomfort, dizziness, swelling, or worsening exercise tolerance that does not seem to fit only with their liver condition.

The confusing part is that portopulmonary hypertension sits at the crossroads of the liver, lungs, blood vessels, and right side of the heart. It is not simply “fluid in the lungs,” and it is not the same as hepatopulmonary syndrome. In portopulmonary hypertension, the small arteries carrying blood through the lungs become narrowed, stiff, or abnormally reactive. This raises resistance in the lung circulation, forcing the right side of the heart to pump against higher pressure. Over time, this can lead to right-sided heart strain or right heart failure if it is not recognized and treated.

Portopulmonary hypertension is generally defined as pulmonary arterial hypertension that occurs in the setting of portal hypertension, with or without advanced cirrhosis. Recent pulmonary hypertension definitions classify pulmonary hypertension by a mean pulmonary arterial pressure greater than 20 millimeters of mercury at rest, measured by right heart catheterization; pulmonary arterial hypertension also requires elevated pulmonary vascular resistance and a normal pulmonary arterial wedge pressure, helping separate it from pressure caused mainly by left-sided heart disease. ^[1]

The word “portopulmonary” combines two ideas:

“Porto” refers to portal hypertension, which means high pressure in the portal venous system. This is the blood vessel system that brings blood from the digestive organs to the liver.

“Pulmonary hypertension” means high blood pressure in the blood vessels of the lungs.

So, portopulmonary hypertension means high pressure in the lung arteries that develops in a person who has portal hypertension. It is considered a form of pulmonary arterial hypertension, not just a general breathing problem. It can occur in people with cirrhosis, but cirrhosis is not always required; the key underlying link is portal hypertension. ^[2] (ScienceDirect)

In simple language, the liver problem creates changes in circulation and blood vessel signaling that can eventually affect the lung arteries. These lung arteries may tighten, thicken, and remodel. Once the pulmonary vascular resistance rises, the right ventricle of the heart has to work harder to push blood through the lungs.

This is why portopulmonary hypertension is not just a liver diagnosis. It is a liver-lung-heart condition.

At first, it may seem strange that liver disease can cause high blood pressure in the lungs. The liver and lungs are separate organs, but they are connected through circulation, inflammation, blood vessel signaling, and the way the body handles chemicals that affect blood vessel tone.

In portal hypertension, blood flow through the liver becomes difficult. This commonly happens in cirrhosis, where scarring changes the structure of the liver. As pressure rises in the portal system, the body forms alternate pathways, called portosystemic shunts, that allow some blood to bypass the liver. This can reduce the liver’s normal filtering effect.

When blood bypasses the liver, certain substances that would usually be processed or balanced may reach the lung circulation in higher amounts. These substances can affect the lining of the pulmonary blood vessels, known as the endothelium. Over time, this may contribute to narrowing of the pulmonary arteries, inflammation, smooth muscle growth, and vascular remodeling. Reviews of portopulmonary hypertension describe mechanisms involving endothelial dysfunction, pulmonary vasoconstriction, and remodeling of the pulmonary vascular bed. ^[2]

Another important factor is the high-flow circulation often seen in advanced liver disease. Many patients with cirrhosis have a hyperdynamic circulation, meaning the heart pumps a higher volume of blood than usual. High blood flow alone can raise pressure readings, but portopulmonary hypertension is different because the resistance inside the lung blood vessels also becomes abnormally high. That distinction is important because not every elevated lung pressure reading in cirrhosis means true portopulmonary hypertension. ^[3]

Portopulmonary hypertension is closely tied to portal hypertension. Portal hypertension may be caused by cirrhosis from chronic viral hepatitis, alcohol-associated liver disease, metabolic dysfunction-associated steatotic liver disease, autoimmune liver disease, or other chronic liver conditions. It may also occur in some non-cirrhotic vascular disorders.

Common signs of portal hypertension include fluid in the abdomen, enlarged veins in the food pipe or stomach, enlarged spleen, low platelet count, and visible collateral veins. However, a patient may not always connect these liver-related signs with breathlessness or reduced stamina.

This is why the diagnosis can be delayed. A person with chronic liver disease may assume that fatigue and poor exercise tolerance are part of liver disease itself. Doctors may also consider anemia, fluid overload, deconditioning, lung disease, heart disease, or infection before the possibility of portopulmonary hypertension is raised.

The important point is this: in a person with portal hypertension, unexplained shortness of breath should not be ignored. It deserves a careful evaluation because portopulmonary hypertension can affect treatment options, quality of life, and liver transplant planning.

Portopulmonary hypertension can be silent in the early stages. Some patients are diagnosed during routine liver transplant screening before they have obvious symptoms. When symptoms do appear, they are often nonspecific and can overlap with liver disease, anemia, fluid retention, and general weakness.

Common symptoms may include shortness of breath on exertion, tiredness, reduced ability to walk or climb stairs, chest pressure, dizziness, fainting episodes, swelling in the legs, abdominal fullness, rapid heartbeat, or worsening fluid retention. As pulmonary arterial pressure and pulmonary vascular resistance increase, the right side of the heart may begin to struggle. This can lead to right-sided heart failure, which may worsen swelling and fatigue.

These symptoms can be misleading because cirrhosis itself can cause weakness, muscle loss, anemia, fluid overload, and poor stamina. That is why testing is often needed to separate liver-related tiredness from a lung blood vessel problem. Expert reviews describe portopulmonary hypertension as a progressive pulmonary vascular disease that can cause right heart strain and influence liver transplant risk.^[3]

One of the most common areas of confusion is the difference between portopulmonary hypertension and hepatopulmonary syndrome. Both conditions can occur in people with liver disease and portal hypertension. Both can cause breathing-related symptoms. But they are not the same condition.

In portopulmonary hypertension, the pulmonary arteries become narrowed or resistant, causing high pressure in the lung circulation. The main problem is increased resistance to blood flow through the lungs.

In hepatopulmonary syndrome, the lung blood vessels become abnormally widened, which can allow blood to pass through the lungs without picking up enough oxygen. The main problem is low oxygen due to abnormal blood vessel dilation and impaired oxygen exchange.

This difference matters. Portopulmonary hypertension can make liver transplant surgery risky if the pressure and resistance in the lung circulation are too high. Hepatopulmonary syndrome, on the other hand, is often evaluated around oxygen levels and may improve after liver transplantation in selected patients. Reviews discussing liver-related pulmonary vascular disease emphasize that portopulmonary hypertension and hepatopulmonary syndrome are distinct complications with different mechanisms, diagnosis, and transplant implications. ^[4]

Portopulmonary hypertension is usually suspected first on an echocardiogram. An echocardiogram is an ultrasound of the heart. It can estimate pressure in the lung circulation, assess the right side of the heart, and look for other cardiac causes of shortness of breath.

However, an echocardiogram alone cannot confirm portopulmonary hypertension. The confirmatory test is right heart catheterization. During this test, doctors directly measure pressures inside the right side of the heart and pulmonary arteries. They also measure cardiac output and pulmonary vascular resistance. Current pulmonary hypertension guidance emphasizes a three-step approach: clinical suspicion, detection by echocardiography, and confirmation with right heart catheterization in experienced centers. ^[1]

Right heart catheterization is important because liver disease can create several different hemodynamic patterns. Some patients may have high pulmonary pressure because of high blood flow. Others may have high pressure because of fluid overload or left-sided heart disease. True portopulmonary hypertension requires a pre-capillary pulmonary arterial hypertension pattern, meaning the resistance in the pulmonary arteries is elevated and the wedge pressure is not high.

This distinction is not just technical. It changes treatment. A patient with high-flow circulation or fluid overload may need a different approach than a patient with true pulmonary arterial narrowing and elevated pulmonary vascular resistance.

Portopulmonary hypertension is especially important in patients being evaluated for liver transplantation. Major surgery and anesthesia place stress on the heart and lungs. If the pulmonary arteries are severely narrowed and the right side of the heart is already under pressure, liver transplant surgery can become dangerous.

Severe portopulmonary hypertension has historically been considered a contraindication to liver transplantation because of increased perioperative mortality risk. At the same time, selected patients may improve with pulmonary arterial hypertension-specific therapy, and some patients may be able to proceed to transplant after pressures and resistance improve. ^[3]

This is one reason portopulmonary hypertension screening is commonly included in transplant workups. A patient may feel frustrated when a liver transplant evaluation suddenly leads to heart and lung testing, but that testing can be lifesaving. The transplant team needs to know whether the right ventricle can tolerate surgery and whether pulmonary vascular resistance is controlled enough for transplant to be considered.

Another important point is that mean pulmonary arterial pressure alone does not tell the whole story. In advanced liver disease, pressure may be affected by blood flow, pulmonary vascular resistance, and wedge pressure. Expert analysis has emphasized that transplant risk assessment should consider pressure, resistance, flow, and right ventricular function together rather than relying on one number in isolation. ^[3]

Treatment depends on severity, symptoms, right heart function, liver disease status, and transplant plans. Management usually involves a team approach with hepatology, pulmonary hypertension specialists, cardiology, and transplant specialists when appropriate.

Pulmonary arterial hypertension-targeted medications may be used in selected patients. These can include medicines that relax or remodel the pulmonary blood vessels, such as phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, prostacyclin pathway therapies, or soluble guanylate cyclase stimulators. These medicines are not interchangeable and should be chosen carefully, especially because liver disease can affect drug metabolism and side effects.

The goal of treatment is to lower pulmonary vascular resistance, reduce right heart strain, improve symptoms, and, in transplant candidates, improve surgical risk when possible. Treatment can improve hemodynamics in some patients, but it is not something patients should start or adjust on their own. Some medications used for pulmonary arterial hypertension require liver function monitoring, blood pressure monitoring, pregnancy precautions, or specialized administration.

Supportive care may also be important. This may include managing fluid overload, treating anemia if present, avoiding unnecessary strain on the heart, assessing oxygen needs, and addressing other contributors to breathlessness. Diuretics may help fluid overload, but overuse can worsen kidney function or blood pressure in people with cirrhosis, so this requires careful supervision.

Portopulmonary hypertension can improve in some patients, especially with appropriate pulmonary arterial hypertension-specific therapy. In certain transplant candidates, treatment may reduce pulmonary vascular resistance enough to allow liver transplantation to be reconsidered. Some patients experience improvement after successful liver transplantation, although this is not guaranteed.

The relationship between liver transplant and portopulmonary hypertension is complex. Unlike many other forms of pulmonary arterial hypertension, portopulmonary hypertension may improve after the underlying portal hypertension is corrected by liver transplant. However, transplant is not safe for everyone with this condition. The risk depends on severity, pulmonary vascular resistance, right ventricular function, response to therapy, and the patient’s overall condition. ^[3]

This is why early detection matters. A patient diagnosed at a milder stage may have more time for treatment optimization. A patient diagnosed only when the right heart is already failing may face fewer options and higher risk.

Screening is especially important for people with portal hypertension who are being evaluated for liver transplant. It may also be considered when a patient with liver disease has unexplained shortness of breath, reduced exercise capacity, fainting, chest discomfort, signs of right heart strain, or an echocardiogram showing elevated pulmonary pressures.

Not every patient with cirrhosis has portopulmonary hypertension. In fact, it is relatively uncommon compared with other complications of cirrhosis. But because it can strongly affect transplant eligibility and survival risk, missing it can have major consequences.

A practical warning sign is breathlessness that seems out of proportion to the liver disease, anemia, or fluid retention. Another is a patient who feels progressively more limited while walking despite stable liver tests. In such cases, doctors may consider echocardiography and, if needed, referral to a pulmonary hypertension center.

Patients who are told they may have portopulmonary hypertension often feel overwhelmed. It can help to ask specific questions:

Is my lung pressure only estimated on echocardiogram, or has it been confirmed by right heart catheterization?

Do I have true pulmonary arterial hypertension, or could the pressure be from high blood flow, fluid overload, or left-sided heart disease?

What is my pulmonary vascular resistance?

How is the right side of my heart functioning?

Do I need treatment from a pulmonary hypertension specialist?

Could this affect my liver transplant eligibility?

Will treatment be aimed at symptoms, transplant clearance, or both?

These questions help patients understand whether they have a screening abnormality or a confirmed diagnosis. They also help clarify the treatment goal.

Living with both liver disease and portopulmonary hypertension can be challenging because symptoms often overlap. Fatigue may come from liver disease, anemia, muscle loss, poor sleep, medication effects, or right heart strain. Swelling may come from cirrhosis, low albumin, kidney issues, or right-sided heart failure. Breathlessness may be related to portopulmonary hypertension, fluid overload, lung disease, or hepatopulmonary syndrome.

This overlap makes regular follow-up important. Patients should report worsening shortness of breath, fainting, chest pain, rapid weight gain, increasing leg swelling, bluish lips, severe dizziness, or sudden reduction in exercise tolerance. These symptoms may suggest worsening heart-lung strain and should not be dismissed as “just liver disease.”

Patients should also avoid starting over-the-counter supplements or alternative medicines without discussing them with their liver team. Some supplements can affect the liver, interact with pulmonary hypertension medicines, or increase bleeding risk in cirrhosis.

Portopulmonary hypertension is a serious but often under-recognized complication of portal hypertension and liver disease. It happens when the lung arteries develop high resistance and high pressure, forcing the right side of the heart to work harder. The condition may cause shortness of breath, fatigue, dizziness, chest discomfort, swelling, or right heart strain, but it can also be discovered during liver transplant screening.

The most important thing to understand is that portopulmonary hypertension is not just a lung problem and not just a liver problem. It is a circulation problem that links portal hypertension, pulmonary blood vessels, and right heart function.

For patients with chronic liver disease, especially those being evaluated for liver transplant, unexplained breathlessness deserves careful evaluation. Echocardiography can raise suspicion, but right heart catheterization is needed to confirm the diagnosis and separate true portopulmonary hypertension from other circulation changes seen in cirrhosis. Early recognition can open the door to targeted treatment, better risk assessment, and safer transplant planning when appropriate.